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Abstract  
Introduction: Despite some improvement in provision of safe drinking water, proper sanitation and hygiene promotion, cholera still remains a 
major public health problem in Malawi with outbreaks occurring almost every year since 1998. In response to 2014/2015 cholera outbreak, 
ministry of health and partners made a decision to assess the feasibility and acceptability of conducting a mass oral cholera vaccine (OCV) as an 
additional public health measure. This paper highlights the burden of the 2014/15 cholera outbreak, successes and challenges of OCV campaign 
conducted in March and April 2015. Methods: This was a documentation of the first OCV campaign conducted in Malawi. The campaign targeted 
over 160,000 people aged one year or more living in 19 camps of people internally displaced by floods and their surrounding communities in 
Nsanje district. It was a reactive campaign as additional measure to improved water, sanitation and hygiene in response to the laboratory 
confirmed cholera outbreak. Results: During the first round of the OCV campaign conducted from 30 March to 4 April 2015, a total of 156,592 
(97.6%) people out of 160,482 target population received OCV. During the second round (20 to 25 April 2015), a total of 137,629 (85.8%) people 
received OCV. Of these, 108,247 (67.6%) people received their second dose while 29,382 (18.3%) were their first dose. Of the 134,836 people 
with known gender and sex who received 1 or 2 doses, 54.4% were females and over half (55.4%) were children under the age of 15 years. 
Among 108,237 people who received 2 doses (fully immunized), 54.4% were females and 51.9% were children under 15 years of age. No severe 
adverse event following immunization was reported. The main reason for non-vaccination or failure to take the 2 doses was absence during the 
period of the campaign. Conclusion: This documentation has demonstrated that it was feasible, acceptable by the community to conduct a large-
scale mass OCV campaign in Malawi within five weeks. Of 320,000 OCV doses received, Malawi managed to administer at least 294,221 (91.9%) of 
the doses. OCV could therefore be considered to be introduced as additional measure in cholera hot spot areas in Malawi. 
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Cholera still remains a significant cause of morbidity and mortality in 
developing countries.World Health Organization (WHO) estimates 
that, every year, there are 3-5 million cholera cases and more than 
100,000 people die of the disease, with the majority (99%) of the 
cases and deaths occurring in Sub-Saharan Africa and Southern Asia 
[1-3].Though the argument on the effectiveness and safety of oral 
cholera vaccine (OCV) existed previously, it has now been agreed 
that OCV can been used as an additional public health measure to 
improved water, sanitation and hygiene promotion to prevent and 
control cholera in endemic areas, epidemic situations and high risk 
populations.The currently WHO prequalified oral killed whole cell 
vaccines can prevent 50% to 65% of cholera episodes in vaccinated 
individuals for five years and also lower the risk in unvaccinated 
neighbours if vaccine coverage is sufficiently high (>50%) [4-6]. In 
Malawi, despite some improvements in access to safe drinking water 
and sanitation, cholera is still a major public health problem with 
outbreaks occurring almost every year since 1998.Unsafe water 
sources, lack of maintenance of broken boreholes, frequent 
interruptions of piped water supply, low coverage of pit latrines 
(range 40%-60%), lack of hand washing facilities (< 5%), salty 
borehole water, fishermen staying on Lake Chilwa, cross-border 
Malawi-Mozambique disease spread, and socio-cultural issues have 
been documented as some of the risk factors for the perpetual 
cholera outbreaks in Malawi [7]. The highest number of cases and 
deaths were reported in 2001/2002 (33,546 cases, 968 deaths; 
attack rate 0.29%, case fatality rate (CFR) 2.3%), 1998/99 (25,000 
cases, 860 deaths; attack rate 0.25%, CFR 3.4%) and 2008/09 
(5,751 cases, 125 deaths; attack rate 0.04%, CFR 2.2%) (Figure 1). 
There are 10 of out 28 districts where cholera outbreaks occur 
frequently (cholera-prone/ high risk districts). These cholera high 
risk districts are also prone to floods. In January 2015, the 10 
cholera high risk districts were among the 15 districts that were 
affected by severe floods which internally displaced over 230,000 
people and killed over 100 persons. The 15 affected districts were 
declared disaster areas by the President of the Republic of Malawi. 
Nsanje was one of the three worst affected districts (the other two 
were Chikwawa and Phalombe). Over 70,000 people were internally 
displaced and were living in 19 temporary shelters. Nsanje was also 
the first district to be affected by a cholera outbreak [8]. The 
cholera outbreak waslaboratory confirmed on 11 February 2015 and 
the cases were cross-border spread from Jambawe gold mine, in 
Mutarara District in Mozambique. By the end of March 2015, a total 
of 176 cholera cases and 3 deaths were reportedin the district and 
the number of new cases per week was increasing [9]. To prevent 
the spread of cholera to camps of internally displaced people, a 
reactive oral cholera vaccine (OCV) campaign was conducted using 
Shanchol® as an additional measure to improved water, sanitation 
and hygiene promotion.Shanchol is one of the oral cholera vaccines 
prequalified by WHO. It is a bivalent (01 and 0139) whole cell killed 
vaccine with an efficacy of 65% at five years [4-5]. A decision was 
therefore made by Ministry of Health and partners to assess the 
feasibility and acceptability of conducting oral cholera mass 
vaccination campaign as an additional public health measure. This 
paper therefore reports the implementation of the first large scale 






Vaccination strategy: this was a reactive campaign in response to 
the laboratory confirmed cholera outbreak. The campaign targeted 
over 160,000 people aged one year or more living in 19 camps of 
internally displaced people and the surrounding communities in 
Nsanje district. The main aim of the campaign was to provide an 
additional public health measure to improved water, sanitation and 
promotion of personal and environmental hygiene to prevent the 
spread of cholera to camps. 
  
Timeline: the campaign was conducted in two rounds. The first 
round was conducted from 30 March to 4 April 2015 and the second 
round took place from 20 to 25 April 2015. Each round was followed 
by a one-day mop up in areas with low coverage. 
  
Floods and cholera outbreak situation: Nsanje (total population 
274,072, 14 health facilities) was one of the districts which 
wereworst hit by floods in January 2015. Over 70,000 people 
(25.5% of the total population) were displaced and were living in 19 
camps. On 11 February 2015, cholera outbreak was laboratory 
confirmed and it was the first district to be affected during 
2014/2015 rainy season. The outbreak was cross-border spread 
from Jambawe gold mine in Mutarara district in Mozambique. By 5 
March 2015, cumulatively, 58 cholera cases and 2 deaths occurred 
in local communities. With 19 camps hosting internally displaced 
people, the threat of a cholera outbreak within the camps was 
imminent. 
  
Vaccine provision: during the first quarter of 2015, the 
International Vaccine Institute (IVI) was planning to allocate 
110,000 doses of the Oral Cholera Vaccine (OCV) for pre-emptive 
use in Nsanje, as part of a collaborative project with the Ministry of 
Health (MOH) and John Snow Inc (JSI). Following the floods and 
the detection of cholera, IVI decided to redirect these doses to 
respond to the emergency. In addition, Ministry of Health submitted 
a request to ICG on 6 March 2015 for additional 210,000 doses. The 
ICG approved the proposal in full on 11 March 2015. A total of 
320,000 OCV doses were therefore sourced from ICG and IVI. 
  
Campaign organization: upon receiving a favourable response 
from ICG of 210,000 additional doses of OCV, a National OCV Task 
Force was set up to plan, budget and oversee the implementation of 
the campaign. A workshop was held to draw up activities and a 
timeline, develop monitoring and evaluation tools (OCV vaccination 
card, register, tally sheet, daily summary sheet, supervision 
checklist, adverse event following immunization form and logistics 
form) and information, education and communication(IEC) 
messages materials and equipment (posters, leaflets, public notices, 
megaphones and letters to community leaders). The campaign 
messages and materials were pre-tested and finalized. Before, 
during and after the OCV campaign, promotion of safe drinking 
water, sanitation and hygiene (WASH) was intensified. Partners 
installed and promoted the use of boreholes and sanitary facilities in 
all the 19 camps of internally displaced people. 
  
Vaccination sites and teams: it was estimated that a team could 
probably vaccinate and document properly about 300 people per 
day. Therefore to be able to reach the target of 160,000 people in 5 
days, a total of 106 (160,000 divided by 300 and by 5) vaccination 
teams were set up. The number of vaccination teams per camp and 
its surrounding community was determined by total population of 
the area divided by 1,500 (number of people that would be 
vaccinated by one team in 5 days). Each vaccination team was 
composed of 4 people (2 vaccinators, 1 recorder and 1 crowd 
controller). Vaccinators were health care workers while recorders 
and crowd controllers were community volunteers. For easy 
supervision and monitoring, the target area was divided in 25 sub-
areas, each with one supervisor. Community mobilization was 
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conducted by vaccinators, volunteers and community leaders in 
their areas one week before and during the campaign. During the 
actual campaign days, a total of 212 vaccinators (106X2), 212 
volunteers, 25 district supervisors, 5 national supervisors and 
partners took part in the campaign. The first round of the campaign 
was conducted from 30 March to 4 April followed by its mop up 
from 9 to 10 April 2015. The second round was conducted from 20 
to 25 April and its mop up from 1 to 2 May 2015. 
  
Data management: data from OCV registers and tally sheets were 
summarized on daily summary sheets. Data from daily summary 
sheets were entered and analyzed in Microsoft excel. Validation and 





Administrative coverage of OCV: during the first round of the 
campaign conducted from 30 March to 4 April 2015, a total of 
156,592 (97.6%) people out of 160,482 target population received 
OCV. During the second round (20 to 25 April 2015), a total of 
137,629 (85.8%) people received OCV. Of these, 108,247 (67.6%) 
people received their second dose while 29,382 (18.3%) were their 
first dose. Of 320,000 OCV doses received, Malawi managed to 
administer 294,221 (91.9%) of the doses. Table 1 and Figure 
2 show detailed administrative coverage by catchment area. 
  
Characteristics of people who received OCV: the 134,836 
people with known gender and sex who received 1 or 2 doses, 
54.4% were females and over half (55.4%) were children under the 
age of 15 years. Among 108,237 people who received 2 doses (fully 
immunized), 54.4% were females and 51.9% were children under 
15 years of age. Among 26,599 people who received their first dose 
during the second round of the campaign, 51.5% were females and 
53.4% were children under 15 years of age (Table 2). 
  
Number of new cholera cases by week and OCV 
campaign: the 2014/2015 outbreak started on 11 February 2015 
and ended on 14 June 2015. Cumulatively, a total of 693 cases and 
11 deaths (CFR 1.6%, attack rate 0.013%) were reported from 
eight districts. Of the 693 cases, 51.2% were females, 10.1% were 
children under 5 years of age, 26.3% were aged 5 to 15 years, 
63.6% were adults aged 15 years or more and about one in three 
cases (31.2%) were from Mozambique seeking treatment in Malawi. 
Chikwawa, Nsanje and Blantyre accounted for 374 (54.0%), 225 
(32.5%) and 65 (9.4%) of the cases respectively. The other five 
districts reported 29(4.2%) cases (Ntcheu 10, Mwanza 9, Lilongwe 
7, Phalombe 2 and Dedza 1). In Nsanje, Cholera outbreak was 
controlled within two weeks after the second round of OCV 
campaign while in Chikwawa and Blantyre it persisted for 5 to 6 
weeks (Figure 3). 
  
Adverse event following immunization: no severe adverse 
event following immunization was reported. Few people (not 






This documentation has demonstrated that it was both feasible and 
acceptable in Malawi to conduct a large-scale OCV mass vaccination 
campaign where 300,000 doses were administered. High 
administrative coverage was achieved in the first and second round; 
97.6% and 85.8% respectively with no serious adverse event 
following immunization reported. High coverage suggests that OCV 
was acceptable by the community. More children under age of 15 
years (55.4%) and females (54.4%) were vaccinated. Coverage for 
fully immunized (two doses) was relatively low 67.6%. The main 
reason for non-vaccination or failure to take second dose was 
absence during the campaign period. These results were similar to 
those achieved in Guinea, South Sudan and Ethiopia [10-13]. 
Another lesson learnt from this campaign was that it was possible to 
conduct the campaign (first round) within five weeks after making a 
decision. After making a decision, Malawi developed a proposal 
within a week and submitted to International Coordination Group 
(ICG) on 6 March 2015. The ICG approved it on 11 March 2015 and 
the vaccines (210,000 doses) were shipped into Malawi within two 
weeks and were immediately transported to health facilities. Within 
this period of two weeks after approval, the National task force was 
set up, materials (training guide, registers, tally sheets, vaccination 
card, information education and communication materials, daily 
summary sheets, supervision forms, logistics forms) were developed 
and printed, health workers and volunteers were briefed, and 
community mobilization was conducted concurrently. This campaign 
also demonstrated that it was logistically possible to use the existing 
vaccine cold chain system of expanded programme of immunization 
(EPI) to store over 300,000 OCV doses. The national and regional 
EPI cold rooms had adequate space for additional vaccines. At 
district level, cold room space was available for at least half the 
quantity of OCV sourced. The other half was kept at a regional 
vaccine store room and was taken to the district to replenish the 
supply. 
  
Limitations of the study 
  
This study made use of the available health facility data and reports 
on cholera outbreak and oral cholera vaccine campaign. The use of 
health facility data has its own limitations, such as incompleteness 
and bias in the sense that the information is obtained only from 
people who came to health facilities. Information could not 
therefore be obtained from non-vaccinated. These limitations 
affected this study just as they would affect any other study that 
uses facility data. Nevertheless, the comprehensive documentation 
of the first OCV campaign provided local evidence on the feasibility 
and acceptability of OCV as additional public health measure to 
improving access to safe drinking water, sanitation and hygiene 
situation to eliminate cholera in Malawi and in the Eastern and 
Southern Africa. Some of the limitations of health facility-based data 
would be addressed by population-based post vaccine campaign 





This documentation has demonstrated that it was feasible and 
acceptable by the community to conduct a large-scale mass OCV 
campaign in Malawi within five weeks. Of 320,000 OCV doses 
received, Malawi managed to administer at least 294,221 (91.9%) 
of the doses. Oral cholera vaccine could therefore be considered to 
be introduced as additional measure in the cholera hot spot areas in 
Malawi. 
 
What is known about this topic 
 
• In Malawi, cholera is a major public health problem with 
outbreaks occurring almost every year since 1998; 
• It is well documented that the current WHO prequalified 
oral cholera vaccines (OCV) can prevent 50% to 65% of 
cholera episodes in vaccinated individuals for five years; 
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• WHO has therefore recommended that OCV can been 
used as an additional public health measure to improved 
water, sanitation and hygiene promotion to prevent and 
control cholera in endemic areas, epidemic situations and 
high risk populations. 
 
What this study adds 
 
• Malawi became the fourth country in Africa after Guinea, 
South Sudan and Ethiopia to conduct a large-scale mass 
OCV reactive campaign; 
• It was logistically feasible, timely and acceptable by the 
community to administer 92% of the 320,000 OCV doses 
received resulting in high coverage in both round 1 and 
round 2; 
• Oral cholera vaccine could be considered in cholera hot 
spot areas and high risk population as an additional public 
health measure a long side efforts of improving access to 
safe water, sanitation and hygiene for prevention and 
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OCV Campaign Round 2 
2 doses 1 dose 1 or 2 doses 
n n % n % n % n % 
Trinity 17,081 20,196 118.2 14,339 83.9 1,477 8.6 15,816 92.6 
Makhanga 18,810 15,442 82.1 14,205 75.5 1,211 6.4 15,416 82.0 
Tengani 19,374 14,679 75.8 9,219 47.6 4,837 25.0 14,056 72.6 
Nyamithuthu 7,068 7,433 105.2 4,818 68.2 485 6.9 5,303 75.0 
Phokera 8,898 8,301 93.3 6,438 72.4 1,976 22.2 8,414 94.6 
Ndamera 8,744 13,611 155.7 9,113 104.2 2,961 33.9 12,074 138.1 
Mbenje 10,112 10,419 103.0 8,411 83.2 3,743 37.0 12,154 120.2 
Nsanje 33,295 29,362 88.2 15,498 46.5 2,892 8.7 18,390 55.2 
Kalemba 18,116 17,916 98.9 12,056 66.5 6,207 34.3 18,263 100.8 
Sorgin 12,930 12,277 94.9 8,295 64.2 2,911 22.5 11,206 86.7 
Sankhulani 6,054 6,956 114.9 5,855 96.7 682 11.3 6,537 108.0 




Table 2: round 2 OCV campaign coverage by gender and sex in Nsanje, Malawi: April- May 2015 
Age 
(years): 
2 doses 1 dose 1 or 2 doses 
  
  
Male Female Both sexes Male Female Both sexes Male Female Both sexes 
n % n % n % n % n % n % n % n % n % 
1-4 7,970 16.4 8,849 14.9 16,819 15.5 2,034 15.8 1,963 14.3 3,997 15.0 10,004 16.3 10,812 14.8 20,816 15.4 
5-14 21,643 44.5 22,065 37.0 43,708 40.4 5,159 40.0 5,042 36.8 10,201 38.4 26,802 43.5 27,107 37.0 53,909 40.0 
15 or 
more 
19,043 39.1 28,667 48.1 47,710 44.1 5,695 44.2 6,706 48.9 12,401 46.6 24,738 40.2 35,373 48.3 60,111 44.6 









Page number not for citation purposes 6
 





Figure 3: Number of OCV doses administered per round per health facility catchment area in Nsanje: March-May 2015 
 
 
